Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
UK legislation to streamline gene-editing technology research is promising for innovation, but presents potential complications for IP, finds Sarah Speight.
The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.
South Africa’s Supreme Court has declared regulations on complementary medicines invalid, explain Kareema Shaik and Jenny Pienaar of Adams & Adams.
A pressing need for more non-invasive prenatal tests is leading to increasing IP activity and commercial interest, say Fran Salisbury and Alice Jefferies of Mewburn Ellis.
The ‘joint applicants’ approach to PCT applications would provide an elegant solution to issues of who is entitled to priority claims in PCT applications, suggests Chiara Banas of EIP.
A new referral to the European Patent Office’s enlarged board of appeal will determine whether post-filed data can be used to support inventive steps in patentability, as Sarah Gibbs of Appleyard Lees reports.
With evidence of antimicrobial resistance increasing, can innovation incentives drive pharma to fight back? Donald McNab and Mark Schuster of Marks & Clerk explore.
Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.
A seemingly small decision by the US Court of Appeals for the Federal Circuit could have a big impact on owners of design patents, explains Elizabeth Ferrill of Finnegan.